Abstract
Introduction Mozambique provides targeted services to reduce HIV incidence and improve clinical outcomes among key populations (KP), including female sex workers (FSW), men who have sex with men (MSM), prisoners, and people who inject drugs (PWID). KP program data were analyzed to understand achievements since 2020 and remaining gaps.
Methods We analyzed PEPFAR Monitoring, Evaluation, and Reporting routine aggregate data available for 2020–2023. KPs on antiretroviral therapy (ART) were defined as clients with ≤28 days since the last missed visit. The test positivity rate was calculated as positive tests over tests conducted. The viral load suppression (VLS) rate was calculated as KP with VLS (<1,000 copies/mL) among those tested in the past 12 months. Data were analyzed by fiscal year (October–September) and KP sub-group.
Results During 2020–2023, tests conducted increased by 176% (43,834 to 121,184), positive tests increased by 33% (10,412 to 13,883) and test positivity was 17% (56,494/333,194); KP newly initiated on ART increased by 198% (3,979 to 11,875); and KP on ART increased by 370% (8,042 to 37,779). Among KP on ART in September 2023, 25,900 (69%) were FSW, 6,601 (17%) were MSM, 4,078 (11%) were prisoners, and 1,200 (3%) were PWID; VLS rate was 94% (23,224/24,723); 94% among FSW (16,451/17,551), 95% among MSM (4,195/4,419), 94% among prisoners (1,837/1,956), and 93% among PWID (741/797).
Conclusion The successful scale-up of KP services in Mozambique since 2020 has increased the number of KP tested, initiated, and sustained on treatment, with high VLS rates. This indicates the positive impact of services among KP, contributing to reaching HIV epidemic control nationally.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used PEPFAR Monitoring, Evaluation, and Reporting program.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available from PEPFAR Monitoring, Evaluation, and Reporting program data.
